Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen trometamol and Evaluation of In vitro Characteristic Properties

Çoban, Özlem Emir; Değim, Zelihagül

doi:10.4274/tjps.83803

Cited by 9 publications

(7 citation statements)

References 22 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, increasing Erlo bioavailability is a big difficulty. 42 Various techniques, such as liposomes, were used in earlier decades to address Erlo and ATO's low absorption and other constraints. Liposomes can transport both hydrophobic (Erlo) and hydrophilic (ATO) medicines as lipid bilayer vesicles.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Arsenic trioxide and Erlotinib loaded in RGD‐modified nanoliposomes for targeted combination delivery to PC3 and PANC‐1 cell lines

Khosravani

Mir

Mirzaei

et al. 2022

Biotech and App Biochem

View full text Add to dashboard Cite

During the past few years, advances in drag delivery have provided many opportunities in the treatment of various diseases and cancer. Arsenic trioxide (ATO) and Erlotinib (Erlo) are two drugs, approved by the United States Food and Drug Administration to treat cancer, but their use is limited in terms of the toxicity of ATO and the low solubility of Erlo. This study aimed to prepare arginine‐glycine‐aspartic acid (RGD)‐decorated nanoliposomes (NLPs) containing Erlo and ATO (NLPs–ATO–Erlo–RGD) to increase the solubility and reduce the toxicity of Erlo and ATO for cancer treatment. The results of transmission electron microscopy and dynamic light scattering showed that NLPs were synthesized uniformly, with spherical shape morphology and particle sizes between 140 and 160 nm. High‐performance liquid chromatography and ICP–MS results showed that about 90% of the drug was loaded in the NLPs. In comparison with NLPs–ATO–Erlo, NLPs–ATO–Erlo–RGD demonstrated considerable toxicity against the αvβ3 overexpressing PC3 cell line in the MTT experiment. It had no effect on the PANC‐1 cell line. In addition, apoptosis assays using Annexin V/PI demonstrated that NLPs–ATO–Erlo–RGD generated the highest apoptotic rates in PC3 cells when compared with NLPs–ATO–Erlo and the combination of free ATO and Erlo. Furthermore, treatment with NLPs–ATO–Erlo–RGD in (p < 0.05) PC3 cell line significantly reduced EGFR level. It is concluded NLPs–ATO–Erlo–RGD as a novel drug delivery system may be a promising platform for the treatment of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Erlo is a medication that is not very water soluble. As a result, increasing Erlo bioavailability is a big difficulty 42 . Various techniques, such as liposomes, were used in earlier decades to address Erlo and ATO's low absorption and other constraints.…”

Section: Discussionmentioning

confidence: 99%

Arsenic trioxide and Erlotinib loaded in RGD‐modified nanoliposomes for targeted combination delivery to PC3 and PANC‐1 cell lines

Khosravani

Mir

Mirzaei

et al. 2022

Biotech and App Biochem

View full text Add to dashboard Cite

show abstract

“…1) Gefitinib Gefitinib was approved by the FDA in 2003 for the treatment of patients with advanced NSCLC who have failed chemotherapy [105]. Erlotinib was approved by the FDA in 2004 for the treatment of locally advanced or metastatic NSCLC and was subsequently approved in combination with gemcitabine for the treatment of locally advanced or metastatic pancreatic cancer [106]. The discovery of the deletion mutation in exon EGFR19 (exon19del) and the base substitution mutation L858R in exon 21 (L858R mutation), a sensitive marker, uncovered the reason why some people are sensitive to EGFR inhibitors.…”

Section: Egfr Inhibitorsmentioning

confidence: 99%

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

Zhou¹,

Peng²,

Wang³

et al. 2023

Preprint

View full text Add to dashboard Cite

In recent years, the FDA has approved numerous antitumor drugs that are mutation-based for clinical use. These drugs have improved the precision of treatment and reduced adverse effects and side effects. Personalized therapy is a prominent and hot topic of current medicine and also represents the future direction of development. With the continuous advancements in gene sequencing and high-throughput screening, research and development strategies for personalized clinical drugs have developed rapidly. This review elaborated the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation aided drug design. These technologies rely on the molecular classification of diseases, the global signaling network within organisms, and new models for all targets, which significantly support the development of personalized medicine. Meanwhile, we summarized chemical drugs such as lorlatinib, osimertinib, and other natural products that deliver personalized therapeutic effects based on genetic mutations. This review also highlights potential challenges in interpreting genetic mutations and combining drugs, while providing new ideas for the development of personalized medicine and pharmacogenomics in cancer study.

show abstract

“…Its analysis is done at an angle of detection of 90° and at a temperature of 30±2°C. The mean vesicle size is expressed in terms of volume mean diameter D, which is the average diameter of a sphere having volume same as that of the particle under measurement 40,41 .…”

Section: Characterization Of Nanocochleate: Determination Of Particle Size Distribution: the Laser Diffraction Technique Uses Malvern 200mentioning

confidence: 99%

Untitled

2021

IJPSR

View full text Add to dashboard Cite

Nanocochleate is a novel lipid-based drug delivery system in which the liposomal vesicles are converted into nanocochleate by the addition of Calcium divalent cation. This technology involves encochleation of the drug for overcoming problems such as poor solubility, poor permeability, and poor oral bioavailability. This novel lipid-based formulation approach is applicable for the category of drugs like BCS class III drugs, BCS class IV drugs. Applications of this technology can also be extended to macromolecules as well as small molecule drugs that are lipophilic with poor oral bioavailability. It is appropriate for oral as well as systemic administration of biologically active molecules, including drugs, genes, proteins, peptides, and vaccine antigens. This article covers multiple aspects of Nanocochleate drug delivery system, such as its definition, composition, method of preparation, and mechanism of permeation. The article also elaborates on various advantages, disadvantages, and applications of Nanocochleate drug delivery system. The article highlights the potential of this novel system for oral as well as systemic delivery of chemical and biological drug products. INTRODUCTION:Successful delivery of biological molecule-based pharmaceutical products is primarily determined by its ability to cross the various barriers in the human body. Various barriers encountered by the delivery system include enzymatic barriers, intestinal epithelial barriers, capillary endothelial barriers, blood-brain barrier (BBB) 1 . The Oral route is the most common and acceptable route for drug delivery due to advantages such as high patient compliance, non-invasiveness, convenience, and acceptability. However, it is challenging to deliver biological molecules like protein and peptides, vaccines, genes, etc. by oral route due to reasons such as:

show abstract

Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen trometamol and Evaluation of In vitro Characteristic Properties

Cited by 9 publications

References 22 publications

Arsenic trioxide and Erlotinib loaded in RGD‐modified nanoliposomes for targeted combination delivery to PC3 and PANC‐1 cell lines

Arsenic trioxide and Erlotinib loaded in RGD‐modified nanoliposomes for targeted combination delivery to PC3 and PANC‐1 cell lines

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

Untitled

Contact Info

Product

Resources

About